First-in-Class Honeybee Vaccine Receives Conditional License from the USDA Center for Veterinary Biologics

Rhea-AI Summary

Dalan Animal Health announced that the USDA has granted a conditional license for a vaccine to protect honeybees from American Foulbrood disease, a major threat to agriculture. This vaccine is a major advancement, as it enables prevention rather than the previous method of euthanizing infected hives. Developed by Dalan and manufactured by Diamond Animal Health, the non-GMO vaccine is anticipated to be on the market in 2023. This innovation aims to enhance honeybee health and secure global food production, as honeybees are crucial for pollination.

Positive

• USDA granted a conditional license for a honeybee vaccine.
• The vaccine presents a sustainable alternative to current treatment methods.
• Expected availability of the vaccine in 2023 could meet a critical agricultural need.

Negative

• None.

ATHENS, Ga.--(BUSINESS WIRE)-- Dalan Animal Health, Inc. (“Dalan”), a biotech company pioneering insect health, announced today that the U.S. Department of Agriculture (USDA) granted a conditional license for vaccination of honeybees against American Foulbrood disease caused by Paenibacillus larvae.

Honeybees are a critical component of agriculture. One-third of the global food supply relies on pollination, and healthy commercial hives are essential to secure high crop yields. However, honeybees are plagued by American Foulbrood, with previously no safe and sustainable solution for disease prevention. Overt clinical cases of American Foulbrood are notifiable in the USA and Canada, and the only treatment method relies on the incineration of bees and infected hives and equipment.

“This is an exciting step forward for beekeepers, as we rely on antibiotic treatment that has limited effectiveness and requires lots of time and energy to apply to our hives,” explained Trevor Tauzer, owner of Tauzer Apiaries and board member of the California State Beekeepers Association. “If we can prevent an infection in our hives, we can avoid costly treatments and focus our energy on other important elements of keeping our bees healthy.”

“We are committed to providing innovative solutions to protect our pollinators and promote sustainable agriculture. Global population growth and changing climates will increase the importance of honeybee pollination to secure our food supply. Our vaccine is a breakthrough in protecting honeybees. We are ready to change how we care for insects, impacting food production on a global scale,” said Dr. Annette Kleiser, CEO of Dalan Animal Health.

The bacterin was developed by Dalan Animal Health, and is manufactured by Diamond Animal Health (Des Moines, IA), a wholly-owned subsidiary of Heska (“Heska”; NASDAQ: HSKA). “We are grateful for the help and assistance that Diamond has been able to offer – not just in manufacturing development, but also regulatory expertise,” said Kleiser. The USDA has issued the conditional license in the first instance for two years. Dalan will distribute the vaccine on a limited basis to commercial beekeepers and anticipates having the vaccine available for purchase in the United States in 2023.

About the vaccine

The vaccine, which contains killed whole-cell Paenibacillus larvae bacteria, is administered by mixing it into queen feed which is consumed by worker bees. The vaccine is incorporated into the royal jelly by the worker bees, who then feed it to the queen. She ingests it, and fragments of the vaccine are deposited in her ovaries. Having been exposed to the vaccine, the developing larvae have immunity as they hatch. Pivotal efficacy studies have indicated that oral vaccination of honeybees may reduce larval death associated with American Foulbrood infections caused by P. larvae. The vaccine is non-GMO and can be used in organic agriculture.

About Dalan Animal Health, Inc

Dalan Animal Health (www.dalan.com) seeks to prevent diseases that affect invertebrates to increase the profitability and yield to producers worldwide. The company’s platform technology uses a transgenerational immune priming approach whereby the maternal animal passes immune modulators (e.g., antigens, anti-microbial molecules) to the next generation larvae before they hatch. The company intends to use this approach to develop vaccines for other honeybee diseases and underserved industries, such as shrimp, mealworms, and insects used in agriculture. The company’s headquarters is in Athens, Georgia, at the University of Georgia’s Innovation Hub.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230104005262/en/

Ian Murphy

press@dalan.com

(310) 689-6397

Source: Dalan Animal Health, Inc.

FAQ

What is the significance of Dalan Animal Health's vaccine for honeybees?

The vaccine addresses American Foulbrood disease, significantly reducing the need for euthanasia of infected hives.

When will the honeybee vaccine by Dalan Animal Health be available?

The vaccine is anticipated to be available for purchase in the United States in 2023.

What is the main benefit of the honeybee vaccine developed by Dalan Animal Health?

It offers a preventative solution, potentially reducing costs and labor associated with current treatments.

How does the honeybee vaccine work?

The vaccine is mixed into queen feed and incorporated into royal jelly, providing immunity to developing larvae.

Which organization granted the license for Dalan's honeybee vaccine?

The U.S. Department of Agriculture (USDA) granted the conditional license.